Three phase III trial results presented at the 2026 American Society of Clinical Oncology annual meeting in Chicago this weekend delivered what oncologists are already calling the most consequential plenary data in years — including the first drug to nearly double survival for patients with metastatic pancreatic cancer, a genomic test that can spare two-thirds of high-risk breast cancer patients from chemotherapy, and a bispecific antibody that beat a standard immunotherapy regimen head-to-head in squamous lung cancer. For patients and their physicians, all three results carry immediate implications: one drug is already in expanded access and heading toward a priority FDA review, one test is commercially available now, and one new drug candidate reached an FDA filing milestone months ago.
ASCO 2026 runs through June 2 at Chicago's McCormick Place Convention Center, with more than 44,000 oncology professionals in attendance.
What Are the Three Biggest Cancer Breakthroughs From ASCO 2026?
The three results — in pancreatic cancer, early-stage breast cancer, and squamous non-small cell lung cancer — each represent a fundamentally different kind of advance. One is a new drug targeting a genetic driver that researchers spent four decades trying to hit. One is a diagnostic test that prevents a harmful treatment from being given to patients who will not benefit from it. One is a next-generation immunotherapy molecule that simultaneously blocks two pathways cancer exploits. Together, they represent a rare convergence of practice-changing results at a single conference.
Daraxonrasib Beats Pancreatic Cancer's 'Undruggable' Gene, Cuts Death Risk 60%
Pancreatic cancer kills roughly 50,000 Americans every year, and approximately 90% of patients carry a mutation in the KRAS gene — a protein so structurally smooth that researchers labeled it "undruggable" for more than four decades. That label changed in 2013 when scientists identified a small, previously undetected binding pocket in KRAS, and it changed decisively on May 31 when Revolution Medicines presented the primary analysis of its phase III RASolute 302 trial at the ASCO plenary session — results simultaneously published in the New England Journal of Medicine.
Daraxonrasib, an oral once-daily pill that targets the active, "switched-on" form of RAS proteins across multiple mutation types, cut the risk of death by 60% compared with standard-of-care chemotherapy in patients who had already received one prior line of treatment. Median overall survival was 13.2 months in the daraxonrasib group versus 6.7 months for those receiving investigator-choice chemotherapy — a hazard ratio of 0.40, with a p-value below 0.0001. The 500-person global trial enrolled patients from North America, Europe, and Asia.
"This is the first RAS inhibitor evaluated in a large, randomized trial for patients with pancreatic cancer," said Brian Wolpin, MD, MPH, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute and the trial's principal investigator, addressing a packed auditorium that responded with a standing ovation. ASCO Chief Medical Officer Julie Gralow called the finding "a grand slam." Rachna Shroff, MD, of the University of Arizona Cancer Center, called it "a game changer."
What makes the result particularly important is its breadth: daraxonrasib was effective regardless of which specific RAS mutation a patient carried — including the rare cases where the gene is not mutated at all. That means physicians do not need to screen for a specific KRAS subtype before prescribing, a practical advantage over earlier, mutation-specific inhibitors. The drug also produced fewer severe side effects than chemotherapy: 43.6% of daraxonrasib patients experienced grade 3 or higher adverse events, compared with 57.5% in the chemotherapy group.
The FDA has already granted daraxonrasib Breakthrough Therapy and Orphan Drug designations, and issued a safe-to-proceed letter for an expanded access program on May 1, 2026, allowing eligible patients outside of clinical trials to begin receiving the drug. Revolution Medicines announced in April that it intends to submit a new drug application under the FDA's Commissioner's National Priority Voucher program — a designation that compresses the standard review timeline from ten months to six months. Requests for expanded access must be initiated by a licensed treating physician on behalf of the patient.
There are caveats. The drug's price has not been set, and targeted oncology therapies have historically cost tens of thousands of dollars per month. Emil Lou, MD, a medical oncologist at the University of Minnesota, noted that most cancer patients receive care in community settings rather than large university hospitals, raising equity concerns about access. Daraxonrasib is not yet approved by any regulatory authority, and researchers are already working to understand how cancers may develop resistance to it.
Prosigna Genomic Test Identifies Breast Cancer Patients Who Can Skip Chemotherapy
The second major result came from a very different direction: not a new drug, but evidence that a commercially available test can identify which patients with a common breast cancer subtype do not need a treatment they have historically been given.
The phase III OPTIMA trial — led by Professor Rob Stein of the UCL Cancer Institute, with co-chief investigator Professor Iain MacPherson of the University of Glasgow, and presented at ASCO on May 30 — enrolled 4,429 patients with early-stage estrogen receptor-positive, HER2-negative breast cancer, the most common breast cancer subtype worldwide. Using the Prosigna test, which analyzes the activity of 50 genes in a tumor sample and assigns a Risk of Recurrence score, the trial found that patients whose tumors scored low could safely skip chemotherapy and be treated with hormone therapy alone, with equivalent five-year invasive breast-cancer-free survival outcomes.
In the trial, approximately 68% of patients tested — all of whom had clinical features that would traditionally qualify them for chemotherapy — had low genomic risk scores. For that group, 93.6% treated with hormone therapy alone were alive and recurrence-free at five years, compared with 94.8% who received chemotherapy: a difference so narrow that the researchers calculated chemotherapy prevents at most two recurrences for every 100 patients treated in this group. "OPTIMA addresses a long-standing challenge in breast cancer care: identifying who truly benefits from chemotherapy and who does not," Stein said. "Our findings show that many patients can safely avoid chemotherapy without compromising their outcomes."
The trial was conducted across the United Kingdom, Norway, Sweden, Australia, New Zealand, and Thailand. Researchers estimate the findings could spare more than 5,000 NHS breast cancer patients per year from chemotherapy. Globally, given that hormone receptor-positive, HER2-negative disease accounts for the majority of new breast cancer diagnoses, the potential scale of chemo de-escalation is substantial.
Oncologists at the meeting flagged one meaningful friction point before routine adoption in the United States: current clinical guidelines from the National Comprehensive Cancer Network recommend a different genomic test — Oncotype DX — for early-stage invasive breast cancer. Switching to Prosigna would represent a paradigm shift requiring guideline revision. Arielle Heeke, MD, of Atrium Health Levine Cancer Institute, noted that more long-term follow-up data would be valuable before full implementation. The trial also excluded patients under 40 and enrolled a predominantly White population, limiting direct applicability to all patients.
The Prosigna test is manufactured by Veracyte, which provided approximately £1.8 million in funding and testing support for the OPTIMA trial alongside primary funding from the UK National Institute for Health and Care Research.
Ivonescimab Beats PD-1 Inhibitor in Squamous Lung Cancer Head-to-Head Trial
The third plenary result came from the HARMONI-6 trial, which tested ivonescimab — a bispecific antibody developed by China's Akeso and licensed outside China to Summit Therapeutics — against tislelizumab plus chemotherapy in 532 patients with previously untreated advanced squamous non-small cell lung cancer. Results were simultaneously published in The Lancet.
Squamous non-small cell lung cancer accounts for roughly one-quarter of all lung cancer cases and has historically lagged behind other lung cancer subtypes in targeted treatment options. Against that backdrop, a 34% reduction in the risk of death versus a PD-1 immunotherapy combination — median overall survival of 27.89 months versus 23.69 months — crossed the trial's prespecified efficacy threshold at a median follow-up of 21.4 months. Professor Shun Lu of Shanghai Chest Hospital, the trial's principal investigator, noted this was the first time a China-originated investigational oncology drug had been selected for the ASCO plenary in the society's 61-year history.
What makes ivonescimab mechanistically distinctive is its dual-target design: a single molecule simultaneously blocks PD-1 — the pathway cancer exploits to hide from immune cells — and VEGF, a protein that promotes tumor blood vessel growth. Combining both functions in one antibody is designed to avoid the overlapping toxicities seen when the two pathways are targeted with separate drugs. In the HARMONI-6 data, ivonescimab extended survival even in patients whose tumors expressed very low levels of PD-L1, a biomarker that normally predicts poor response to PD-1 blockade — a meaningful finding for the subset of squamous NSCLC patients who do not respond to standard immunotherapy.
Independent oncologists raised a critical caveat: HARMONI-6 was conducted entirely at 50 sites in China and enrolled only Chinese patients. Suresh Ramalingam, MD, of Emory University, noted that Chinese patients have historically responded differently to PD-1 and VEGF therapies, which may account for part of the observed benefit. Deborah Doroshow, MD, of Mount Sinai, said it "is not clear how meaningful" the four-month survival advantage is without data from Western populations. A separate global trial — HARMONi-3 — is underway in populations including the United States and Europe to test whether the benefit holds. Summit Therapeutics has submitted a separate FDA application for ivonescimab in a different lung cancer subtype, with a PDUFA target date of November 14, 2026, but no U.S. regulatory filing has yet been made for the squamous indication covered by HARMONI-6.
Three Cancers, Immediate Questions for Patients
For patients and caregivers, the practical question is: what can be done with these results today?
For metastatic pancreatic cancer patients who have received at least one prior treatment, daraxonrasib is currently available through the FDA-authorized expanded access program. Their oncologist — not the patient directly — can apply through Revolution Medicines. The drug has not been approved, and insurance coverage remains uncertain, but access outside of clinical trials now exists.
For patients with early-stage, hormone receptor-positive, HER2-negative breast cancer, the Prosigna test is commercially available and can be ordered by an oncologist. Patients who score in the low-risk range — as OPTIMA now demonstrates — have strong phase III evidence that chemotherapy provides minimal additional benefit. The conversation about skipping it is now firmly supported by clinical data, though physician awareness of OPTIMA results and guideline alignment will take time to filter through standard practice.
For squamous non-small cell lung cancer patients, ivonescimab is not yet approved in Western markets for this indication. Ongoing global trials will determine whether HARMONI-6's survival benefit holds in non-Asian populations before Western regulatory filings for squamous NSCLC are expected.
Frequently Asked Questions
What is daraxonrasib, and is it available to patients now?
Daraxonrasib is an oral, once-daily RAS inhibitor developed by Revolution Medicines that targets the KRAS gene mutation found in more than 90% of pancreatic cancer cases. It is not yet FDA-approved, but the agency authorized an expanded access program on May 1, 2026, allowing eligible patients with previously treated metastatic pancreatic cancer to receive it outside of a clinical trial. Access must be requested by a licensed treating physician. A formal new drug application is expected to be filed under an expedited review pathway.
What does the OPTIMA breast cancer trial mean for patients currently facing chemotherapy decisions?
The OPTIMA results are relevant for patients with newly diagnosed early-stage estrogen receptor-positive, HER2-negative breast cancer who are weighing adjuvant treatment options after surgery. The Prosigna test — which analyzes 50 genes in the tumor — can now be used to identify whether chemotherapy is likely to offer meaningful benefit. For those who score in the low-risk range, the OPTIMA phase III data show that hormone therapy alone produces nearly identical five-year outcomes. Patients should ask their oncologist whether the test is available at their institution.
How does ivonescimab work differently from standard immunotherapy?
Standard PD-1 immunotherapy drugs block a single pathway cancer uses to evade immune cells. Ivonescimab is a bispecific antibody that simultaneously blocks PD-1 and VEGF — a second protein that drives tumor blood vessel growth — in a single molecule. The HARMONI-6 trial showed this approach outperformed a PD-1 drug plus chemotherapy in squamous lung cancer, though the trial was conducted entirely in China, and independent oncologists have said results in Western patients may differ. A global trial is underway to answer that question.
What makes ASCO 2026 historically significant for cancer research?
ASCO 2026 produced multiple phase III results that oncologists are describing as practice-changing: the first drug to nearly double survival in metastatic pancreatic cancer after four decades of failed attempts to target KRAS; the largest randomized evidence base for chemotherapy de-escalation in common breast cancer; and the first China-originated oncology drug to reach the ASCO plenary in the society's 61-year history. The convergence of three landmark results across three major cancer types in a single meeting is unusual by any measure.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission.
